Compared side by side
BPC-157 vs larazotide: how they differ
The short answer
Both are aimed at the gut, from different angles: larazotide is an oral drug candidate that blocks the zonulin pathway to keep the junctions between gut cells closed, and BPC-157 is a peptide that, in animal studies, protects and repairs the gut lining. Larazotide reached phase 3 trials in celiac disease but was never approved, and in its celiac trials the gut-permeability test didn’t change. Larazotide is taken by mouth 3 times a day with meals; BPC-157 is mostly injected, once or twice daily.
Side by side
| Compared | BPC-157 | Larazotide |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Body Protection Compound 157, BPC157 | AT-1001, Larazotide Acetate |
| What it is | A peptide derived from a protective protein in your stomach. | An oral drug candidate aimed at the 'gates' between cells in your gut lining: it blocks the zonulin pathway to keep them closed. |
| How it works | Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining. | Tight junction regulator that blocks the zonulin pathway to reduce gut permeability; in cell and animal studies it tightens the junctions between gut cells. In human celiac trials the gut-permeability test didn't change. Phase 2 trials were run in celiac disease, and a phase 3 was stopped in 2022 after an interim analysis. |
| Commonly reported | Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots. | Less bloating and post-meal discomfort, though many notice little. It reached phase 3 trials in celiac disease but was never approved. |
| Studied range | Research range: 200–500 mcg. Studied in research — not a recommendation. | Research range: 0.5–1 mg. Studied in research — not a recommendation. |
| How often | Once or twice daily | 3x daily with meals |
| Half-life | ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes) | Very short (local gut action) |
| Route | SubQ injection, IM injection, Oral (less studied) | Oral |
| Typical run | Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely. | Typically used for 4–12 weeks alongside gut healing protocols. |
| Evidence | Emerging: primarily preclinical / limited human data | Moderate: animal studies + some human data |
| Common side effects | Nausea (rare), injection site irritation, vivid dreams, dizziness | Generally well tolerated, mild GI upset, nausea |
- Category
- BPC-157Healing & recovery
- LarazotideHealing & recovery
- Also known as
- BPC-157Body Protection Compound 157, BPC157
- LarazotideAT-1001, Larazotide Acetate
- What it is
- BPC-157A peptide derived from a protective protein in your stomach.
- LarazotideAn oral drug candidate aimed at the 'gates' between cells in your gut lining: it blocks the zonulin pathway to keep them closed.
- How it works
- BPC-157Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
- LarazotideTight junction regulator that blocks the zonulin pathway to reduce gut permeability; in cell and animal studies it tightens the junctions between gut cells. In human celiac trials the gut-permeability test didn't change. Phase 2 trials were run in celiac disease, and a phase 3 was stopped in 2022 after an interim analysis.
- Commonly reported
- BPC-157Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
- LarazotideLess bloating and post-meal discomfort, though many notice little. It reached phase 3 trials in celiac disease but was never approved.
- Studied range
- BPC-157Research range: 200–500 mcg. Studied in research — not a recommendation.
- LarazotideResearch range: 0.5–1 mg. Studied in research — not a recommendation.
- How often
- BPC-157Once or twice daily
- Larazotide3x daily with meals
- Half-life
- BPC-157~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
- LarazotideVery short (local gut action)
- Route
- BPC-157SubQ injection, IM injection, Oral (less studied)
- LarazotideOral
- Typical run
- BPC-157Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.
- LarazotideTypically used for 4–12 weeks alongside gut healing protocols.
- Evidence
- BPC-157Emerging: primarily preclinical / limited human data
- LarazotideModerate: animal studies + some human data
- Common side effects
- BPC-157Nausea (rare), injection site irritation, vivid dreams, dizziness
- LarazotideGenerally well tolerated, mild GI upset, nausea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
BPC-157
- Day 1–7 Week one: early hints, for some
- Day 7–14 Pain often starts to ease
- Day 14–21 Pain often eases by week three
- Day 21–28 Many report a calmer gut
- Day 28–42 The slower part of repair
- Day 42–56 Six weeks in: taking stock
- Day 84+ Past week 12, the data runs thin
Larazotide
- Day 1–14 Early days at the gut lining
- Day 14–42 What users notice in weeks 2 to 6
- Day 42–84 Taper or maintain
Together or one or the other
BPC-157 and larazotide are a common stack: larazotide lists BPC-157 among its common stacks.
Community · Larazotide
Gut repair trio
Three layers of the same problem: larazotide targets the gaps between gut cells, BPC-157 supports deeper repair of the gut lining, and KPV damps the inflammation in between. A common practitioner stack for gut recovery. Commonly reported: calmer digestion over several weeks.
Questions people ask
How long do BPC-157 and larazotide last?
The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes). The half-life of larazotide is very short (local gut action).
How often are BPC-157 and larazotide taken?
BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied). Larazotide: 3x daily with meals. Route: Oral.
How are BPC-157 and larazotide dosed in research?
The research range for BPC-157 is 200–500 mcg. The research range for larazotide is 0.5–1 mg. Studied in research — not a recommendation.
What are the common side effects of BPC-157 and larazotide?
For BPC-157, the library lists: nausea (rare), injection site irritation, vivid dreams, dizziness. For larazotide: generally well tolerated, mild GI upset, nausea.
Are BPC-157 and larazotide taken together?
BPC-157 and larazotide are a common stack: larazotide lists BPC-157 among its common stacks. Three layers of the same problem: larazotide targets the gaps between gut cells, BPC-157 supports deeper repair of the gut lining, and KPV damps the inflammation in between. A common practitioner stack for gut recovery. Commonly reported: calmer digestion over several weeks.